Eli Lilly’s existing October 2024 non-exclusive evaluation agreement with Peptron covers only internal R&D use of the SmartDepot PLGA microsphere platform for long-acting peptide formulations, with any commercial rights requiring a separate binding deal. That evaluation contract was extended to a maximum of 24 months and remains in the data-review stage as of early 2026, with no public disclosure of commercial licensing terms, manufacturing rights, or technology-transfer milestones. Lilly’s June 2025 exclusive global licensing agreement with Camurus for its competing FluidCrystal platform further reduces near-term urgency for a Peptron commercial deal. With the October 7, 2026 resolution date roughly four months away and no announced progress or new catalysts, traders assign a 74% implied probability to “No.”
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado$10,111 Vol.
$10,111 Vol.
7 oct 2026
$10,111 Vol.
$10,111 Vol.
7 oct 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 non-exclusive evaluation agreement with Peptron covers only internal R&D use of the SmartDepot PLGA microsphere platform for long-acting peptide formulations, with any commercial rights requiring a separate binding deal. That evaluation contract was extended to a maximum of 24 months and remains in the data-review stage as of early 2026, with no public disclosure of commercial licensing terms, manufacturing rights, or technology-transfer milestones. Lilly’s June 2025 exclusive global licensing agreement with Camurus for its competing FluidCrystal platform further reduces near-term urgency for a Peptron commercial deal. With the October 7, 2026 resolution date roughly four months away and no announced progress or new catalysts, traders assign a 74% implied probability to “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Mercado abierto: May 5, 2026, 8:02 PM ET
Volumen
$10,111Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s existing October 2024 non-exclusive evaluation agreement with Peptron covers only internal R&D use of the SmartDepot PLGA microsphere platform for long-acting peptide formulations, with any commercial rights requiring a separate binding deal. That evaluation contract was extended to a maximum of 24 months and remains in the data-review stage as of early 2026, with no public disclosure of commercial licensing terms, manufacturing rights, or technology-transfer milestones. Lilly’s June 2025 exclusive global licensing agreement with Camurus for its competing FluidCrystal platform further reduces near-term urgency for a Peptron commercial deal. With the October 7, 2026 resolution date roughly four months away and no announced progress or new catalysts, traders assign a 74% implied probability to “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volumen
$10,111Fecha de finalización
7 oct 2026Mercado abierto
May 5, 2026, 8:02 PM ETResolver
0x65070BE91...Eli Lilly’s existing October 2024 non-exclusive evaluation agreement with Peptron covers only internal R&D use of the SmartDepot PLGA microsphere platform for long-acting peptide formulations, with any commercial rights requiring a separate binding deal. That evaluation contract was extended to a maximum of 24 months and remains in the data-review stage as of early 2026, with no public disclosure of commercial licensing terms, manufacturing rights, or technology-transfer milestones. Lilly’s June 2025 exclusive global licensing agreement with Camurus for its competing FluidCrystal platform further reduces near-term urgency for a Peptron commercial deal. With the October 7, 2026 resolution date roughly four months away and no announced progress or new catalysts, traders assign a 74% implied probability to “No.”
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes